Novo Nordisk’s (NVO) semaglutide recently delivered results in two late-stage clinical trials testing a 7.2mg dose of the drug, which found that tripling the dose from 2.4mg led to increased weight loss, Svenja Nierwetberg of The Financial Times reports. Patients lost an average of 19% of their body weight after 72 weeks, compared to 16% on the 2.4 mg dose. While the results fell short of Eli Lilly’s (LLY) tirzepatide, if priced competitively, semaglutide could become a more affordable alternative.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk’s Drug Trial Achieves 19% Weight Loss, Fuels Rivalry with Eli Lilly
- Mixed options sentiment in Novo Nordisk with shares up 1.15%
- Microsoft, OpenAI sign MOU for next phase of partnership: Morning Buzz
- Novo Nordisk tells workers to return to office, Bloomberg reports
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!